## Neil Ruparelia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9080906/publications.pdf

Version: 2024-02-01

331670 289244 1,733 67 21 40 citations h-index g-index papers 68 68 68 3193 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nature Reviews Cardiology, 2017, 14, 133-144.	13.7	338
2	Long-Term Durability of TranscatheterÂAortic Valve Prostheses. Journal of the American College of Cardiology, 2019, 73, 537-545.	2.8	193
3	Acute myocardial infarction activates distinct inflammation and proliferation pathways in circulating monocytes, prior to recruitment, and identified through conserved transcriptional responses in mice and humans. European Heart Journal, 2015, 36, 1923-1934.	2.2	88
4	Coronary Hemodynamics in Patients WithÂSevere Aortic Stenosis and Coronary Artery Disease Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 2019-2031.	2.9	88
5	Inflammation and atherosclerosis: what is on the horizon?. Heart, 2020, 106, 80-85.	2.9	61
6	Myocardial infarction causes inflammation and leukocyte recruitment at remote sites in the myocardium and in the renal glomerulus. Inflammation Research, 2013, 62, 515-525.	4.0	60
7	Molecular Magnetic Resonance Imaging of Angiogenesis In Vivo using Polyvalent Cyclic RGD-Iron Oxide Microparticle Conjugates. Theranostics, 2015, 5, 515-529.	10.0	54
8	Drug-Coated Balloons Versus Second-Generation Drug-Eluting Stents forÂthe Management of Recurrent Multimetal-Layered In-Stent Restenosis. JACC: Cardiovascular Interventions, 2015, 8, 1586-1594.	2.9	43
9	Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery. British Journal of Ophthalmology, 2014, 98, 1320-1324.	3.9	42
10	Short-Term and Long-Term Outcomes After Polytetrafluoroethylene-Covered Stent Implantation for the Treatment of Coronary Perforation. American Journal of Cardiology, 2015, 116, 1822-1826.	1.6	41
11	Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. International Journal of Cardiology, 2018, 250, 66-72.	1.7	33
12	Bioresorbable vascular scaffold use for coronary bifurcation lesions: A substudy from GHOST EU registry. Catheterization and Cardiovascular Interventions, 2017, 89, 47-56.	1.7	28
13	Effects of niacin on atherosclerosis and vascular function. Current Opinion in Cardiology, 2011, 26, 66-70.	1.8	27
14	Who Is Thrombogenic: The Scaffold or the Doctor? Back to the Future!. JACC: Cardiovascular Interventions, 2016, 9, 25-27.	2.9	27
15	Left atrial appendage closure: A single center experience and comparison of two contemporary devices. Catheterization and Cardiovascular Interventions, 2017, 89, 763-772.	1.7	27
16	The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: a comparison with conventional balloon predilatation. EuroIntervention, 2016, 11, e1580-e1588.	3.2	26
17	TAVI in 2015: who, where and how?. Heart, 2015, 101, 1422-1431.	2.9	24
18	Paravalvular leak closure under intracardiac echocardiographic guidance. Catheterization and Cardiovascular Interventions, 2018, 91, 958-965.	1.7	24

#	Article	IF	CITATIONS
19	A propensity score matched comparative study between paclitaxelâ€coated balloon and everolimusâ€eluting stents for the treatment of small coronary vessels. Catheterization and Cardiovascular Interventions, 2017, 90, 380-386.	1.7	23
20	Comparison of the self-expanding Evolut-PRO transcatheter aortic valve to its predecessor Evolut-R in the real world multicenter ATLAS registry. International Journal of Cardiology, 2020, 310, 120-125.	1.7	23
21	Differential Gene Expression in Macrophages From Human Atherosclerotic Plaques Shows Convergence on Pathways Implicated by Genome-Wide Association Study Risk Variants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2718-2730.	2.4	20
22	Determining the Predominant Lesion in Patients With Severe Aortic Stenosis and Coronary Stenoses. Circulation: Cardiovascular Interventions, 2019, 12, e008263.	3.9	20
23	Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing <scp>TAVI</scp> for severe aortic stenosis: Insights from the <scp>WINâ€₹AVI</scp> registry. Catheterization and Cardiovascular Interventions, 2021, 97, 516-526.	1.7	17
24	Bioresorbable Scaffolds for theÂManagement of Coronary BifurcationÂLesions. JACC: Cardiovascular Interventions, 2016, 9, 989-1000.	2.9	16
25	Long-Term Outcomes After Transcatheter Aortic Valve Implantation from a Single High-Volume Center (The Milan Experience). American Journal of Cardiology, 2016, 117, 813-819.	1.6	16
26	Valve embolization with a second-generation fully-retrievable and repositionable transcatheter aortic valve. International Journal of Cardiology, 2016, 223, 867-869.	1.7	13
27	Percutaneous Transcatheter Treatment for Tricuspid Bioprosthesis Failure. Catheterization and Cardiovascular Interventions, 2016, 88, 994-1001.	1.7	13
28	Initial experience of a large, selfâ€expanding, and fully recapturable transcatheter aortic valve: The UK & Ireland Implanters' registry. Catheterization and Cardiovascular Interventions, 2019, 93, 751-757.	1.7	13
29	Impact of post-procedural hyperglycemia on acute kidney injury after transcatheter aortic valve implantation. International Journal of Cardiology, 2016, 221, 892-897.	1.7	12
30	Bicuspid Aortic Valve Endocarditis Complicated by Mitral Valve Aneurysm. Journal of Cardiac Surgery, 2011, 26, 284-286.	0.7	11
31	Use of Double Stiff Wire Allows Successful Transfemoral Transcatheter Aortic Valve Implantation Through Extreme Thoracic Aorta Tortuosity. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	9
32	Impact of clinical and procedural factors upon C reactive protein dynamics following transcatheter aortic valve implantation. World Journal of Cardiology, 2016, 8, 425.	1.5	9
33	Positive Vessel Remodeling and Appearance of Pulsatile Wall Motion at Long-Term Follow-Up After BioresorbableÂScaffold Implantation in a Chronic Total Occlusion. JACC: Cardiovascular Interventions, 2015, 8, 1635-1637.	2.9	7
34	Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions. International Journal of Cardiology, 2017, 246, 26-31.	1.7	7
35	Percutaneous left atrial appendage occlusion with the Amulet device: The impact of device disc position upon periprocedural and longâ€ŧerm outcomes. Catheterization and Cardiovascular Interventions, 2019, 93, 120-127.	1.7	7
36	Procedural and thirty-day outcomes following transfemoral implantation of the fully repositionable and retrievable Lotus valve without routine pre-dilatation in a consecutive patient cohort: a single-center experience. Cardiovascular Revascularization Medicine, 2018, 19, 78-82.	0.8	6

#	Article	IF	Citations
37	The missing acute coronary syndromes in the COVID-19 era. Therapeutic Advances in Cardiovascular Disease, 2020, 14, 175394472097773.	2.1	6
38	Placebo-Controlled Efficacy of Percutaneous Coronary Intervention for Focal and Diffuse Patterns of Stable Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2021, 14, e009891.	3.9	6
39	Successful Treatment of Very Early Thrombosis of SAPIEN 3 Valve with Direct Oral Anticoagulant Therapy. Journal of Heart Valve Disease, 2016, 25, 211-213.	0.5	6
40	Transcatheter aortic valve implantation – what the general physician needs to know. Clinical Medicine, 2015, 15, 420-425.	1.9	5
41	Management of failing bioprosthesis in elderly patients who have undergone transcatheter aortic valve replacement. Expert Review of Medical Devices, 2017, 14, 763-771.	2.8	4
42	Left ventricular speckle tracking echocardiographic evaluation before and after TAVI. Echo Research and Practice, 2020, 7, 29-38.	2.5	4
43	71â€Percutaneous Coronary Intervention (PCI) Risk Scores Predicting Inpatient Mortality and Major Adverse Cardiac Events (MACE) are Poorly Concordant in High Risk Patients. Heart, 2014, 100, A41.2-A42.	2.9	3
44	The Relentless Attempt to Perfect the 2-Stent Technique. JACC: Cardiovascular Interventions, 2015, 8, 960-961.	2.9	3
45	Role of coronary physiology in the contemporary management of coronary artery disease. World Journal of Clinical Cases, 2015, 3, 148.	0.8	3
46	Very Late Restenosis After Bioresorbable Scaffold Implantation Due to Simultaneous External Compression of the Scaffold and Intrascaffold Tissue Growth. JACC: Cardiovascular Interventions, 2016, 9, e15-e17.	2.9	3
47	A comparison of the fully repositionable and retrievable B oston L otus and direct flow medical valves for the treatment of severe aortic stenosis: A single center experience. Catheterization and Cardiovascular Interventions, 2018, 91, 966-974.	1.7	3
48	Double Utility of a Buddy Wire inÂTransseptal Transcatheter MitralÂIntervention. JACC: Cardiovascular Interventions, 2019, 12, 2555-2557.	2.9	3
49	Proportion of acute ischaemic strokes attributable to a cardiac aetiology in an unselected young patient population: A single centre experience. Clinical Medicine, 2020, 20, 174-177.	1.9	3
50	Aortic Valve Calcium Score Is Associated With Acute Stroke in Transcatheter Aortic Valve Replacement Patients., 2022, 1, 100349.		3
51	Severe Neointimal Hyperplasia of Neoplastic Carina Following Bioresorbable Scaffold Implantation Using T-Stenting andASmall Protrusion Technique. JACC: Cardiovascular Interventions, 2015, 8, e207-e209.	2.9	2
52	Clinical outcomes following bioresorbable scaffold implantation in small vessels. International Journal of Cardiology, 2016, 207, 59-61.	1.7	2
53	A Novel Technique for Prosthetic Valve Retrieval After Transcatheter Aortic Valve Embolization. Canadian Journal of Cardiology, 2017, 33, 951.e1-951.e3.	1.7	2
54	Use of a parallel stiff wire to facilitate percutaneous Impella RP ventricular assist device positioning. Cardiovascular Revascularization Medicine, 2017, 18, 54-55.	0.8	2

#	Article	IF	CITATIONS
55	Facilitating rightâ€sided axillary artery access for transcatheter aortic valve replacement using the Edwards Sapien 3 and ultra valves: Technical considerations. Catheterization and Cardiovascular Interventions, 2020, 96, E747-E754.	1.7	2
56	Longitudinal deformation of a third generation zotarolimus eluting stent: "The concertina returns!― World Journal of Cardiology, 2017, 9, 60.	1.5	2
57	Elderly Woman With Nausea and Vomiting. Annals of Emergency Medicine, 2009, 53, 586-593.	0.6	1
58	Is a Drug-Eluting Stent the Default Treatment Strategy for Drug-Eluting StentÂRestenosis?â^—. Journal of the American College of Cardiology, 2015, 66, 34-36.	2.8	1
59	Indications for transcatheter aortic valve implantation – now and next?. Minimally Invasive Therapy and Allied Technologies, 2015, 24, 264-273.	1.2	1
60	Late-acquired scaffold malapposition and discontinuity that may be attributable to pathological coronary ectasia: Insights from optical coherence tomography. International Journal of Cardiology, 2015, 186, 136-138.	1.7	1
61	Rescue Valve-in-Valve-in-Valve TAVR for Acute Transvalvular Aortic Regurgitation. Cardiovascular Revascularization Medicine, 2020, 21, 11-13.	0.8	1
62	Balloon-Assisted Tracking (BAT) of an Uncrossable Aortic Valve During Transcatheter Aortic Valve Implantation. Cardiovascular Revascularization Medicine, 2020, 21, 33-35.	0.8	1
63	Authors' response. British Journal of Ophthalmology, 2014, 98, 1136-1137.	3.9	0
64	Transcatheter mitral valve replacement in severe mitral annular calcification and atrial septal defect closure. Cardiovascular Revascularization Medicine, 2019, 20, 194-196.	0.8	0
65	Percutaneous devices for the treatment of complex native valve mitral leaflet and aortomitral continuity defects: Review and case series. Cardiovascular Revascularization Medicine, 2021, , .	0.8	0
66	Oral anticoagulant therapy for early post-TAVI thrombosis. Interventional Cardiology Review, 2017, 13, 1.	1.6	0
67	Transfemoral Valve-in-Valve Transcatheter Aortic Valve Implantation (TAVI) in a Patient With Previous Endovascular Aortic Repair (EVAR). Journal of Invasive Cardiology, 2016, 28, E69-70.	0.4	O